Clinical Oncology News: Everolimus Ups PFS in Pts With Postmenopausal HR+ Breast Ca

Adding everolimus to fulvestrant improved progression-free survival (PFS) in postmenopausal women with hormone receptor (HR)-positive/HER2-negative, aromatase inhibitor (AI)-resistant metastatic breast cancer during the randomized, Phase II PrECOG 0102 trial.

Read the full story at Clinical Oncology News

Share This Article!